New drug aims to tame dual threat for dialysis patients

NCT ID NCT00542386

Summary

This large, completed Phase 3 trial tested whether the drug MCI-196 could help control two common problems in people with kidney failure on dialysis: high phosphorus and high 'bad' cholesterol. The study involved 642 stable dialysis patients who were randomly assigned to receive either the drug or a placebo for 12 weeks. The main goals were to see if the drug safely lowered blood phosphorus and LDL cholesterol levels compared to the dummy pill.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Study site

    Ajka, Hungary

  • Study site

    Baja, Hungary

  • Study site

    Budapest, Hungary

  • Study site

    Esztergom, Hungary

  • Study site

    Győr, Hungary

  • Study site

    Hatvan, Hungary

  • Study site

    Kisvárda, Hungary

  • Study site

    Lecco, Italy

  • Study site

    Modena, Italy

  • Study site

    Pavia, Italy

  • Study site

    Roma, Italy

  • Study site

    Alor Star, Malaysia

  • Study site

    Ipoh, Malaysia

  • Study site

    Kajang, Malaysia

  • Study site

    Klang, Malaysia

  • Study site

    Kota Kinabalu, Malaysia

  • Study site

    Kuala Terengganu, Malaysia

  • Study site

    Kuantan, Malaysia

  • Study site

    Kuching, Malaysia

  • Study site

    Malacca, Malaysia

  • Study site

    Seremban, Malaysia

  • Study site

    Taiping, Malaysia

  • Study site

    Skopje, North Macedonia

  • Study site

    Lodz, Poland

  • Study site

    Poznan, Poland

  • Study site

    Płock, Poland

  • Study site

    Rybnik, Poland

  • Study site

    Warsaw, Poland

  • Study site

    Wroclaw, Poland

  • Study site

    Zielona Góra, Poland

  • Study site

    Arkhangelsk, Russia

  • Study site

    Armavir, Russia

  • Study site

    Chelyabinsk, Russia

  • Study site

    Chita, Russia

  • Study site

    Irkutsk, Russia

  • Study site

    Ivanovo, Russia

  • Study site

    Kaluga, Russia

  • Study site

    Kemerovo, Russia

  • Study site

    Khabarovsk, Russia

  • Study site

    Krasnodar, Russia

  • Study site

    Krasnoyarsk, Russia

  • Study site

    Moscow, Russia

  • Study site

    Nizhny Novgorod, Russia

  • Study site

    Novokuznetsk, Russia

  • Study site

    Novorossiysk, Russia

  • Study site

    Novosibirsk, Russia

  • Study site

    Omsk, Russia

  • Study site

    Petrozavodsk, Russia

  • Study site

    Rostov-on-Don, Russia

  • Study site

    Saint Petersburg, Russia

  • Study site

    Smolensk, Russia

  • Study site

    Tomsk, Russia

  • Study site

    Tver', Russia

  • Study site

    Tyumen, Russia

  • Study site

    Vladimir, Russia

  • Study site

    Vladivostok, Russia

  • Study site

    Volzhskiy, Russia

  • Study site

    Yaroslavl, Russia

  • Study site

    Yekaterinburg, Russia

  • Study site

    Belgrade, Serbia

  • Study site

    Kragujevac, Serbia

  • Study site

    Niš, Serbia

  • Study site

    Novi Sad, Serbia

  • Study site

    Chernivtsi, Ukraine

  • Study site

    Dnipro, Ukraine

  • Study site

    Ivano-Frankivsk, Ukraine

  • Study site

    Kharkiv, Ukraine

  • Study site

    Kiev, Ukraine

  • Study site

    Mykolaiv, Ukraine

  • Study site

    Ternopil, Ukraine

  • Study site

    Uzhhorod, Ukraine

  • Study site

    Zaporizhya, Ukraine

  • Study site

    Zhytomyr, Ukraine

Conditions

Explore the condition pages connected to this study.